ARRIVENT ANNOUNCES FIRST PATIENT DOSED IN GLOBAL PIVOTAL PHASE 3 ALPACCA TRIAL EVALUATING FIRMONERTINIB FOR FIRST-LINE TREATMENT OF EGFR PACC MUTANT NON-SMALL CELL LUNG CANCER

Reuters · 3d ago

Please log in to view news